Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma (Nature (2017) 547 (217-221) DOI: 10.1038/nature22991);An immunogenic personal neoantigen vaccine for patients with melanoma

Nature

Volumn 547, Issue 7662, 2017, Pages 217-221

  Ott, Patrick A ^a,b,c   Hu, Zhuting ^a   Keskin, Derin B ^a,c,d   Shukla, Sachet A ^a,d   Sun, Jing ^a   Bozym, David J ^a   Zhang, Wandi ^a   Luoma, Adrienne ^a   Giobbie Hurder, Anita ^a   Peter, Lauren ^e,f   Chen, Christina ^a   Olive, Oriol ^a   Carter, Todd A ^d   Li, Shuqiang ^d   Lieb, David J ^d   Eisenhaure, Thomas ^d   Gjini, Evisa ^a   Stevens, Jonathan ^g   Lane, William J ^g   Javeri, Indu ^h   Nellaiappan, Kaliappanadar ^a   Salazar, Andres M ^e   Daley, Heather ^a,b,c   Seaman, Michael ^b,c   Buchbinder, Elizabeth I ^d   Yoon, Charles H ^d   Harden, Maegan ^a,b   Lennon, Niall ^c,e,f   Gabriel, Stacey ^b,c   Rodig, Scott J ^c,d,i   Barouch, Dan H ^a,c   Aster, Jon C ^a,b,c   Getz, Gad ^c,d   Wucherpfennig, Kai ^a,d   Neuberg, Donna ^c,i   Ritz, Jerome ^a   Lander, Eric S ^a   Fritsch, Edward F ^a,d,j   Hacohen, Nir ^c,i   Wu, Catherine J ^a,b,c,d   more..

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^g CuriRx Inc   (United States)

^h Oncovir Inc   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j Neon Therapeutics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; INTERFERON INDUCED HELICASE C DOMAIN CONTAINING PROTEIN 1; NEOANTIGEN VACCINE; PEMBROLIZUMAB; TOLL LIKE RECEPTOR 3; TUMOR ANTIGEN; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ANTIGEN; CANCER; CELLS AND CELL COMPONENTS; DISEASE INCIDENCE; IMMUNE RESPONSE; IMMUNITY; MACHINE LEARNING; PROTEIN; TUMOR; VACCINATION; VACCINE;

ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEASIBILITY STUDY; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INJECTION SITE REACTION; MELANOMA; MELANOMA CELL LINE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RNA SEQUENCE; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; T LYMPHOCYTE SUBPOPULATION; TUMOR REGRESSION; VACCINE IMMUNOGENICITY; WHOLE EXOME SEQUENCING; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CLINICAL TRIAL; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOLOGY; MACHINE LEARNING; MUTATION; PATIENT SAFETY; PERSONALIZED MEDICINE; PREVENTION AND CONTROL; PROCEDURES; TUMOR RECURRENCE;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MACHINE LEARNING; MELANOMA; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATIENT SAFETY; PRECISION MEDICINE; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85024377220     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature25145     Document Type: Erratum

References (45)

1. Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69-74 (2015).
2. Hacohen, N., Fritsch, E. F., Carter, T. A., Lander, E. S. & Wu, C. J. Getting personal with neoantigen-based therapeutic cancer vaccines. Cancer Immunol. Res. 1, 11-15 (2013).
3. Kenter, G. G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847 (2009).
4. Caskey, M. et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 208, 2357-2366 (2011).
5. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521-2532 (2015).
6. Sykulev, Y., Joo, M., Vturina, I., Tsomides, T. J. & Eisen, H. N. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 4, 565-571 (1996).
7. Stephen, T. L. et al. SATB1 expression governs epigenetic repression of PD-1 in tumor-reactive T cells. Immunity 46, 51-64 (2017).
8. Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641-645 (2014).
9. Schumacher, T. et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512, 324-327 (2014).
10. van Rooij, N. et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31, e439-e442 (2013).
11. Rizvi, N. A. et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124-128 (2015).
12. Linnemann, C. et al. High-Throughput epitope discovery reveals frequent recognition of neo-Antigens by CD4+ T cells in human melanoma. Nat. Med. 21, 81-85 (2015).
13. Prickett, T. D. et al. Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol. Res. 4, 669-678 (2016).
14. Carreno, B. M. et al. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348, 803-808 (2015).
15. Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692-696 (2015).
16. Martin, S. D. et al. Low mutation burden in ovarian cancer may limit the utility of neoantigen-Targeted vaccines. PLoS ONE 11, e0155189 (2016).
17. Stern, L. J. et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368, 215-221 (1994).
18. Rossjohn, J. et al. T cell antigen receptor recognition of antigen-presenting molecules. Annu. Rev. Immunol. 33, 169-200 (2015).
19. Falk, K., Rötzschke, O., Stevanović, S., Jung, G. & Rammensee, H. G. Allelespecific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296 (1991).
20. Mildner, A. & Jung, S. Development and function of dendritic cell subsets. Immunity 40, 642-656 (2014).
21. Spitzer, M. H. et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168, 487-502 (2017).
22. Haabeth, O. A. et al. Idiotype-specific CD4+ T cells eradicate disseminated myeloma. Leukemia 30, 1216-1220 (2016).
23. Hirschhorn-Cymerman, D. et al. Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J. Exp. Med. 209, 2113-2126 (2012).
24. Abelin, J. G. et al. Mass spectrometry profiling of HLA-Associated peptidomes in mono-Allelic cells enables more accurate epitope prediction. Immunity 46, 315-326 (2017).
25. Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).
26. Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27, 182-189 (2009).
27. Chapman, M. A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
28. Berger, M. F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
29. Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601-2602 (2011).
30. DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491-498 (2011).
31. Saunders, C. T. et al. Strelka: Accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811-1817 (2012).
32. Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24-26 (2011).
33. Ramos, A. H. et al. Oncotator: cancer variant annotation tool. Hum. Mutat. 36, E2423-E2429 (2015).
34. Torres-García, W. et al. PRADA: pipeline for RNA sequencing data analysis. Bioinformatics 30, 2224-2226 (2014).
35. Hoof, I. et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 61, 1-13 (2009).
36. Lundegaard, C., Lund, O. & Nielsen, M. Prediction of epitopes using neural network based methods. J. Immunol. Methods 374, 26-34 (2011).
37. Roemer, M. G. et al. Classical hodgkin lymphoma with reduced β 2M/MHC Class i expression is associated with inferior outcome independent of 9p24.1 status. Cancer Immunol. Res. 4, 910-916 (2016).
38. Cai, A. et al. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients. Clin. Cancer Res. 18, 5761-5772 (2012).
39. Lu, Y. C. et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clinical Cancer Res. 20, 3401-3410 (2014).
40. Day, C. L. et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J. Clin. Invest. 112, 831-842 (2003).
41. Call, M. J. et al. In vivo enhancement of peptide display by MHC class II molecules with small molecule catalysts of peptide exchange. J. Immunol. 182, 6342-6352 (2009).
42. Hashimshony, T. et al. CEL-seq2: sensitive highly-multiplexed single-cell RNA-seq. Genome Biol. 17, 77 (2016).
43. Satija, R., Farrell, J. A., Gennert, D., Schier, A. F. & Regev, A. Spatial reconstruction of single-cell gene expression data. Nat. Biotechnol. 33, 495-502 (2015).
44. Kharchenko, P. V., Silberstein, L. & Scadden, D. T. Bayesian approach to single-cell differential expression analysis. Nat. Methods 11, 740-742 (2014).
45. Lundegaard, C. et al. NetMHC-3.0: Accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36, W509-12 (2008).